The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
|Videos|October 26, 2017
Dr. Brammer on Brentuximab Vedotin for Patients With T-Cell Lymphoma
Author(s)Jonathan E. Brammer, MD
Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.
Advertisement
Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.
An issue in the landscape that is currently being explored is whether brentuximab vedotin is effective in the frontline setting as has been shown in Hodgkin lymphoma. Preliminary studies have shown that brentuximab vedotin does seem to have some efficacy in other CD30-positive T-cell lymphomas.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Basser Center for BRCA Awards 2026 Global Prize to Judy Garber
4
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
5